Abstract
[Objective]Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody titers level and duration of elevated levels are considered important indicators for confirming the efficacy of coronavirus disease 2019 (COVID–19) vaccines. The objective of this study was to demonstrate the changes in antibody titers after the second and third doses of the COVID–19 vaccine, and to determine the antibody titers in cases of spontaneous infection with SARS-CoV-2 after vaccination.
[Materials and Methods]From June 2021 to February 2023, IgG-type SARS-CoV-2 antibody titers were measured in 127 participants, including 74 outpatients and 53 staffs, at the Osaka Dental University Hospital (65 males and 62 females, mean age 52.3 ± 19.1 years).
[Results]Consistent with previous reports, the SARS-CoV-2 antibody titer decreased with time, not only after the second dose, but also after the third dose of the vaccine if there is no spontaneous COVID–19 infection. We also confirmed that the third booster vaccination was effective in increasing the antibody titer.
21 cases of natural infections were observed after administering two or more doses of the vaccine. 13 of these patients had post-infection antibody titers exceeding 40,000 AU/mL, and some cases continued to maintain antibody titers in the tens of thousands of AU/mL even after more than 6 months had passed since infection.
[Conclusion]The rise in and duration of antibody titers against SARS-CoV-2 are considered important indicators for confirming the efficacy of novel COVID–19 vaccines. A longitudinal follow-up of antibody titers after vaccination in larger studies is warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocols were approved by the ethics committee of Osaka Dental University Hospital (2022-10)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
I re-uploaded.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
